(REGN) Regeneron Pharmaceuticals - Ratings and Ratios
Injection, Antibody, Treatment, Medication, Therapy
REGN EPS (Earnings per Share)
REGN Revenue
Description: REGN Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for various diseases, including eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases, as well as cancer. The companys product portfolio includes treatments for wet age-related macular degeneration, diabetic macular edema, atopic dermatitis, asthma, and certain types of cancer.
From a business perspective, Regeneron has a diverse revenue stream with multiple products, including EYLEA, Dupixent, and Libtayo, which contribute to its revenue growth. The companys partnerships with other biotech firms, such as Mammoth Biosciences and Sonoma Biotherapeutics, demonstrate its commitment to innovative research and development. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and the number of products in its pipeline.
Analyzing Regenerons financials, we can observe that the company has a market capitalization of $61.2 billion and a price-to-earnings ratio of 14.23, indicating a relatively stable valuation. The return on equity (RoE) is 14.77%, suggesting that the company is generating returns on shareholder equity. Other KPIs to monitor include the companys cash and cash equivalents, debt-to-equity ratio, and operating margin.
From a growth perspective, Regenerons pipeline is focused on developing treatments for various diseases, including rare and orphan diseases. The companys ability to successfully develop and commercialize new products will be crucial to its long-term growth. Key areas to watch include the progress of its in vivo CRISPR-based gene editing therapies and engineered regulatory T cell therapies. Additionally, the companys ability to expand its product portfolio through strategic partnerships and acquisitions will be important for its future success.
REGN Stock Overview
| Market Cap in USD | 59,189m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-04-02 |
REGN Stock Ratings
| Growth Rating | -42.5% |
| Fundamental | 78.5% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -57.8% |
| Analyst Rating | 4.28 of 5 |
REGN Dividends
| Dividend Yield 12m | 0.43% |
| Yield on Cost 5y | 0.47% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 1.0% |
| Payout Ratio | 5.8% |
REGN Growth Ratios
| Growth Correlation 3m | 75.7% |
| Growth Correlation 12m | -90.2% |
| Growth Correlation 5y | 51.1% |
| CAGR 5y | -6.46% |
| CAGR/Max DD 3y | -0.11 |
| CAGR/Mean DD 3y | -1.26 |
| Sharpe Ratio 12m | -0.92 |
| Alpha | 0.00 |
| Beta | 0.976 |
| Volatility | 35.03% |
| Current Volume | 707.9k |
| Average Volume 20d | 880.9k |
| Stop Loss | 555.7 (-3.4%) |
| Signal | 0.34 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (4.46b TTM) > 0 and > 6% of Revenue (6% = 852.9m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 1.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 92.81% (prev 115.4%; Δ -22.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 4.74b > Net Income 4.46b (YES >=105%, WARN >=100%) |
| Net Debt (709.3m) to EBITDA (5.42b) ratio: 0.13 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (108.6m) change vs 12m ago -5.89% (target <= -2.0% for YES) |
| Gross Margin 81.98% (prev 82.80%; Δ -0.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.26% (prev 37.38%; Δ 0.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 134.2 (EBITDA TTM 5.42b / Interest Expense TTM 36.6m) >= 6 (WARN >= 3) |
Altman Z'' 10.30
| (A) 0.35 = (Total Current Assets 16.86b - Total Current Liabilities 3.67b) / Total Assets 38.22b |
| (B) 0.88 = Retained Earnings (Balance) 33.68b / Total Assets 38.22b |
| warn (B) unusual magnitude: 0.88 — check mapping/units |
| (C) 0.13 = EBIT TTM 4.91b / Avg Total Assets 37.15b |
| (D) 4.07 = Book Value of Equity 33.73b / Total Liabilities 8.28b |
| Total Rating: 10.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.50
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.70% = 3.35 |
| 3. FCF Margin 27.05% = 6.76 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda 1.04 = 1.71 |
| 6. ROIC - WACC (= 5.62)% = 7.03 |
| 7. RoE 15.11% = 1.26 |
| 8. Rev. Trend 53.36% = 4.00 |
| 9. EPS Trend -1.89% = -0.09 |
What is the price of REGN shares?
Over the past week, the price has changed by +3.33%, over one month by +0.20%, over three months by +10.19% and over the past year by -49.91%.
Is Regeneron Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of REGN is around 453.49 USD . This means that REGN is currently overvalued and has a potential downside of -21.14%.
Is REGN a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the REGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 716.9 | 24.7% |
| Analysts Target Price | 716.9 | 24.7% |
| ValueRay Target Price | 506.9 | -11.9% |
Last update: 2025-09-13 05:04
REGN Fundamental Data Overview
CCE Cash And Equivalents = 7.47b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.3268
P/E Forward = 14.6413
P/S = 4.1641
P/B = 2.0115
P/EG = 1.0929
Beta = 0.35
Revenue TTM = 14.21b USD
EBIT TTM = 4.91b USD
EBITDA TTM = 5.42b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 3.67b USD (from totalCurrentLiabilities, last quarter)
Debt = 5.65b USD (Calculated: Short Term 3.67b + Long Term 1.99b)
Net Debt = 709.3m USD (from netDebt column, last quarter)
Enterprise Value = 57.37b USD (59.19b + Debt 5.65b - CCE 7.47b)
Interest Coverage Ratio = 134.2 (Ebit TTM 4.91b / Interest Expense TTM 36.6m)
FCF Yield = 6.70% (FCF TTM 3.84b / Enterprise Value 57.37b)
FCF Margin = 27.05% (FCF TTM 3.84b / Revenue TTM 14.21b)
Net Margin = 31.37% (Net Income TTM 4.46b / Revenue TTM 14.21b)
Gross Margin = 81.98% ((Revenue TTM 14.21b - Cost of Revenue TTM 2.56b) / Revenue TTM)
Tobins Q-Ratio = 1.70 (Enterprise Value 57.37b / Book Value Of Equity 33.73b)
Interest Expense / Debt = 0.06% (Interest Expense 3.60m / Debt 5.65b)
Taxrate = 7.68% (367.3m / 4.78b)
NOPAT = 4.53b (EBIT 4.91b * (1 - 7.68%))
Current Ratio = 4.60 (Total Current Assets 16.86b / Total Current Liabilities 3.67b)
Debt / Equity = 0.19 (Debt 5.65b / last Quarter total Stockholder Equity 29.94b)
Debt / EBITDA = 1.04 (Net Debt 709.3m / EBITDA 5.42b)
Debt / FCF = 1.47 (Debt 5.65b / FCF TTM 3.84b)
Total Stockholder Equity = 29.50b (last 4 quarters mean)
RoA = 11.67% (Net Income 4.46b, Total Assets 38.22b )
RoE = 15.11% (Net Income TTM 4.46b / Total Stockholder Equity 29.50b)
RoCE = 15.60% (Ebit 4.91b / (Equity 29.50b + L.T.Debt 1.99b))
RoIC = 14.40% (NOPAT 4.53b / Invested Capital 31.49b)
WACC = 8.78% (E(59.19b)/V(64.84b) * Re(9.61%)) + (D(5.65b)/V(64.84b) * Rd(0.06%) * (1-Tc(0.08)))
Shares Correlation 3-Years: -9.23 | Cagr: -0.34%
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.67% ; FCFE base≈3.59b ; Y1≈3.05b ; Y5≈2.33b
Fair Price DCF = 316.6 (DCF Value 32.98b / Shares Outstanding 104.2m; 5y FCF grow -18.28% → 3.0% )
EPS Correlation: -1.89 | EPS CAGR: 5.45% | SUE: 4.0 | # QB: 1
Revenue Correlation: 53.36 | Revenue CAGR: 8.51% | SUE: N/A | # QB: None
Additional Sources for REGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle